In October 2014, Portola Pharmaceuticals announced the completion of Phase I and Phase II clinical trials for andexanet alfa as an antidote for Factor Xa inhibitors with few adverse effects, as well as the start of Phase III trials.
Am Oktober 2014 huet Portola Pharmaceuticals Phase I an II klinesch Verspriechen fir den Andexanet alfa als Antidot fir Factor Xa Inhibitoren mat e puer negativen Effekter fäerdeg gemaach a Phase III trieden ugefaangen.